Xigen SA
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.xigenpharma.com
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 309
- Registration Number
- NCT02508337
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 339
- Registration Number
- NCT02235272
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 260
- Registration Number
- NCT02235259
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 24
- Registration Number
- NCT01570205
- Locations
- 🇨ðŸ‡
Covance Clinical Research, Allschwil, BS, Switzerland
© Copyright 2025. All Rights Reserved by MedPath